Barclays analyst Glen Santangelo raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $16 from $15 and keeps an Overweight rating on the shares. The firm says it has increased confidence in Amneal’s fiscal 2026 setup following the “strong” Q1 report. The company is positioned to close its valuation gap relative to peers and as it accelerates its biosimilar efforts, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX: